Details

Autor(en) / Beteiligte

• Kreuzer, Karl‐Anton
• Saborowski, Antje
• Lupberger, Joachim
• Appelt, Christine
• Na, Il‐Kang
• Le Coutre, Philipp
• Schmidt, Christian Andreas

Titel

Fluorescent 5′‐exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias

Ist Teil von

• British journal of haematology, 2001-08, Vol.114 (2), p.313-318

Ort / Verlag

Oxford, UK: Blackwell Science Ltd

Erscheinungsjahr

2001

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• The Wilms' tumour gene (WT1) has been suggested as a powerful parameter for molecular monitoring of minimal residual disease (MRD) in leukaemias. However, molecular monitoring via WT1 RNA levels is far from being routinely performed, which is possibly owing to the complex and inaccurate quantitative reverse transcription polymerase chain reaction (RT‐PCR) procedures. Using a newly‐developed quantitative real time RT‐PCR, we measured WT1 transcripts in peripheral blood leucocytes of patients with acute myeloid (AML), acute lymphoid (ALL) and chronic myeloid leukaemia (CML). While healthy blood donors did not show measurable amounts of WT1 transcripts, WT1 RNA levels were detectable in all types of leukaemia. Furthermore, intraindividual WT1 transcript kinetics were exclusively dependent on disease progression, treatment and subsequent disease outcome. Using this approach, we could distinguish between treatment response and failure within the first days of therapeutic intervention. Moreover, gradually rising WT1 levels over a period of weeks and months paralleled long‐term disease progression and appeared to be a prognostic indicator for subsequent clinical relapse. A linear correlation between quantities of WT1 and bcr/abl fusion transcripts could be seen in CML. We conclude that quantitative assessment of WT1 transcripts using real‐time PCR is an appropriate method for molecular monitoring of AML, ALL and CML, and can be used independently for both short‐ and long‐term monitoring of leukaemia patients.